Skip to Main Content

U-CH1

General Characteristics

Age: 56 years
Gender: Male
Disease Origin: Sacral
Disease Status: Recurrent
Prior Radiation: Yes
Prior Systemic Therapy: No
Source: Silke Bruderlein, Peter Moller
University of Ulm

Molecular Features

Cell Morphology: Physaliferous
TBXT Expression: Positive; 10x that of U-CH2 with overexpression but no amplification
TBXT Localization: Nuclear
CD24 Expression: Positive; 13x that of U-CH2
HLA Type: A2
Sequence Data:

WGS, Exome and Transcriptome data available: raw sequencing data in Cavatica (Chordoma Foundation Dataset) and summary data in PedcBioPortal. Contact researchteam@chordoma.org with any questions.

SMARCB1 Status:
Validation Results: Validation Report

Growth Conditions

Growth Medium: IMDM: RPMI-1640 (4:1) +10% FBS
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures

Publications

Characterized By:
  • Scheil S, Brüderlein S, Liehr T, Starke H, Herms J et al. (2001) Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32: 203-211. PubMed: 11579460.

Additional References:

  • Scheipl S, Lohberger B, Rinner B, Froehlich EV, Beham A et al. (2013) Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis. J Orthop Res 31(12):1999-2005. PubMed: 23893747.
  • Brüderlein S, Sommer J, Meltzer P, Li S, Osada T et al. (2010) Molecular Characterization of Putative Chordoma Cell Lines. Sarcoma: 630129. PubMed: 21253487.
  • Duan Z, Shen J, Yang X, Yang P, Osaka E et al. (2014) Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res. PubMed: 24501096.
  • Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B et al. (2011) The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 223(3):336-46. PubMed: 21171079.
  • Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M et al. Molecular profiling of chordoma. Int J Oncol 44(4):1041-55. PubMed: 24452533.
  • Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14(7):638-47. PubMed: 23792643.
  • Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J et al. (2010) Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 28(6):746-52. PubMed: 20041488.
  • Yang C, Hornicek F, Wood KB, Schwab JH, Choy E et al. (2010) Characterization and analysis of human chordoma cell lines. Spine 35(13):1257-64. PubMed: 20461036.
  • Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B et al. (2011) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223(3):327-35. PubMed: 21171078.